Company: RGNT
Filing Date: 2025-07-07
Form Type: F-1/A
Source: 0001213900-25-061821
Chunk: 117

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-07-07
Form: F-1/A
Chunk 117
---
 enabling surface erosion completes this mechanism with a receding implant in a planned synchrony with the newly formed cartilage
tissue.

<div align='center'>70</div>

Mode of Action of GelrinC:

| 1. Stelar delivery device                                                                                                                
 membrane covers cartilage lesion. Using a syringe GelrinC is introduced into the lesion.                                                 |     | 2. Upon filing of the lesion,                                                                   
 UV beam cures GelrinC into a soft rubbery implant.                                              |
| 3. As GelrinC implant recedes                                                                                                            
 and resorbs, the cartilage lesion rim creates aggregates and new cartilage tissue filling up the void created by the retreating implant. |     | 4. At the end of 6-9 months                                                                     
 with functioning knee, GelrinC implant is resorbed and new cartilage covers the treated lesion. |

<div align='center'>71</div>

As demonstrated in the Pilot
Study, the advantages of GelrinC include:

| ● | An off-the-shelf product 
 for cartilage repair;    |

| ● | A new class of a-cellular 
 product solution;         |

| ● | Polyethylene glycol, or                                                                                                             
 PEG, implant preventing cellular migration as a primary mode of action and further aided by denatured fibrinogen controlled erosion 
 for the regeneration of hyaline-like cartilage;                                                                                     |

| ● | Initial state as liquid                                                                                                          
 form provides for complete and optimal defect filling and subsequent curing hardens it into a more solid body, and holding it in 
 place;                                                                                                                           |

| ● | Single, 10 minutes surgical 
 procedure;                  |

| ● | Implantable via open or                 
 minimally-invasive surgical techniques; |

| ● | Manufacturing process allows               
 for low cost of goods and scalability; and |

| ● | Intended for the repair                                     
 of focal defects in cartilage and/or osteochondral defects. |

All of these advantages were
demonstrated in the Pilot Study where the recovery of the patient took approximately two weeks of non-weight bearing activity, and led
to a full recovery within three to six months. Additionally, 100% of the participants who were followed up with in the Pilot study reported
no pain in their recovery through at least four years thereafter.

Future Products; Additional Applications

Based on similarity of mechanism
of action for cartilage and based on animal studies performed by the Company for osteoarthritis